Literature DB >> 27485640

Vismodegib and risk of cholestatic injury: should we screen candidate patients?

Michelangelo Vestita1, Lucia Lospalluti2, Giuseppe Giudice1, Domenico Bonamonte2, Ignazio Rossiello3, Angela Filoni4.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27485640     DOI： 10.1007/s10238-016-0433-2

Source DB:  PubMed          Journal:  Clin Exp Med        ISSN： 1591-8890            Impact factor:   3.984


× No keyword cloud information.
  5 in total

1.  Vismodegib-associated hepatotoxicity: a potential side effect detected in postmarketing surveillance.

Authors:  Daniel J Ventarola; David I Silverstein
Journal:  J Am Acad Dermatol       Date:  2014-08       Impact factor: 11.527

2.  Phase I trial of hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with refractory, locally advanced or metastatic solid tumors.

Authors:  Patricia M LoRusso; Charles M Rudin; Josina C Reddy; Raoul Tibes; Glen J Weiss; Mitesh J Borad; Christine L Hann; Julie R Brahmer; Ilsung Chang; Walter C Darbonne; Richard A Graham; Kenn L Zerivitz; Jennifer A Low; Daniel D Von Hoff
Journal:  Clin Cancer Res       Date:  2011-02-07       Impact factor: 12.531

3.  Efficacy and safety of vismodegib in advanced basal-cell carcinoma.

Authors:  Aleksandar Sekulic; Michael R Migden; Anthony E Oro; Luc Dirix; Karl D Lewis; John D Hainsworth; James A Solomon; Simon Yoo; Sarah T Arron; Philip A Friedlander; Ellen Marmur; Charles M Rudin; Anne Lynn S Chang; Jennifer A Low; Howard M Mackey; Robert L Yauch; Richard A Graham; Josina C Reddy; Axel Hauschild
Journal:  N Engl J Med       Date:  2012-06-07       Impact factor: 91.245

4.  Co-administration of vismodegib with rosiglitazone or combined oral contraceptive in patients with locally advanced or metastatic solid tumors: a pharmacokinetic assessment of drug-drug interaction potential.

Authors:  Patricia M LoRusso; Sarina A Piha-Paul; Monica Mita; A Dimitrios Colevas; Vikram Malhi; Dawn Colburn; Ming Yin; Jennifer A Low; Richard A Graham
Journal:  Cancer Chemother Pharmacol       Date:  2012-10-11       Impact factor: 3.333

Review 5.  Cholestatic hepatic injury associated with vismodegib, aspirin, and naproxen use: a case study and review of vismodegib safety.

Authors:  Mark M Ash; Puneet S Jolly
Journal:  Int J Dermatol       Date:  2014-07-11       Impact factor: 2.736
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.